{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:30:40Z","timestamp":1782491440520,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,4]]},"abstract":"Abstract<\/jats:title>\n Purpose<\/jats:title>\n The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer\u2019s disease (AD) and the continued discussions around that decision have increased interest in immunotherapy for AD and other brain diseases. Reliable techniques for brain imaging of antibodies may guide decision-making in the future but needs further development. In this study, we used 89<\/jats:sup>Zr-immuno-PET to evaluate the targeting and distribution of a bispecific brain-shuttle IgG based on Adu with transferrin receptor protein-1 (TfR1) shuttling mechanism, mAbAdu-scFab8D3, designated Adu-8D3, as a candidate theranostic for AD. We also validated the 89<\/jats:sup>Zr-immuno-PET platform as an enabling technology for developing new antibody-based theranostics for brain disorders.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n Adu, Adu-8D3, and the non-binding control construct B12-8D3 were modified with DFO*-NCS and radiolabeled with 89<\/jats:sup>Zr. APP\/PS1 mice were injected with 89<\/jats:sup>Zr-labeled mAbs and imaged on days 3 and 7 by positron emission tomography (PET). Ex vivo<\/jats:italic> biodistribution was performed on day 7, and ex vivo<\/jats:italic> autoradiography and immunofluorescence staining were done on brain tissue to validate the PET imaging results and target engagement with amyloid-\u03b2 plaques. Additionally, [89<\/jats:sup>Zr]Zr-DFO*-Adu-8D3 was evaluated in 3, 7, and 10-month-old APP\/PS1 mice to test its potential in early stage disease.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n A 7-fold higher brain uptake was observed for [89<\/jats:sup>Zr]Zr-DFO*-Adu-8D3 compared to [89<\/jats:sup>Zr]Zr-DFO*-Adu and a 2.7-fold higher uptake compared to [89<\/jats:sup>Zr]Zr-DFO*-B12-8D3 on day 7. Autoradiography and immunofluorescence of [89<\/jats:sup>Zr]Zr-DFO*-Adu-8D3 showed co-localization with amyloid plaques, which was not the case with the Adu and B12-8D3 conjugates. [89<\/jats:sup>Zr]Zr-DFO*-Adu-8D3 was able to detect low plaque load in 3-month-old APP\/PS1 mice.<\/jats:p>\n <\/jats:sec>\n Conclusion<\/jats:title>\n 89<\/jats:sup>Zr-DFO*-immuno-PET revealed high and specific uptake of the bispecific Adu-8D3 in the brain and can be used for the early detection of A\u03b2 plaque pathology. Here, we demonstrate that 89<\/jats:sup>Zr-DFO*-immuno-PET can be used to visualize and quantify brain uptake of mAbs and contribute to the evaluation of biological therapeutics for brain diseases.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00259-023-06109-3","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T02:02:30Z","timestamp":1673575350000},"page":"1306-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-\u00df monoclonal antibody"],"prefix":"10.1007","volume":"50","author":[{"given":"N.","family":"Stergiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. E.","family":"Wuensche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Mes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Verlaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J. M.","family":"Kooijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Helboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vergo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Asuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A. M. S.","family":"Van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bang-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Vugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2216-4439","authenticated-orcid":false,"given":"W.","family":"Beaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"issue":"2","key":"6109_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11910-020-01090-y","volume":"21","author":"T Ayodele","year":"2021","unstructured":"Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C. Early-onset Alzheimer\u2019s disease: what is missing in research? Curr Neurol Neurosci Rep. 2021;21(2):4. https:\/\/doi.org\/10.1007\/s11910-020-01090-y.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"6109_CR2","unstructured":"Gauthier S, Rosa-Neto P, Morais JA, & Webster C. World Alzheimer Report 2021: journey through the diagnosis of dementia. London, England: Alzheimer\u2019s Disease International. 2021. Available from: https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2021."},{"issue":"4","key":"6109_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3233\/JAD-141134","volume":"43","author":"C Takizawa","year":"2015","unstructured":"Takizawa C, Thompson PL, van Walsem A, Faure C, Maier WC. Epidemiological and economic burden of Alzheimer\u2019s disease: a systematic literature review of data across Europe and the United States of America. J Alzheimers Dis. 2015;43(4):1271\u201384. https:\/\/doi.org\/10.3233\/JAD-141134.","journal-title":"J Alzheimers Dis"},{"key":"6109_CR4","doi-asserted-by":"publisher","unstructured":"Weller J, Budson A. Current understanding of Alzheimer\u2019s disease diagnosis and treatment. F1000Res. 2018;7.\u00a0https:\/\/doi.org\/10.12688\/f1000research.14506.1.","DOI":"10.12688\/f1000research.14506.1"},{"issue":"1","key":"6109_CR5","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189. https:\/\/doi.org\/10.1101\/cshperspect.a006189.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"2","key":"6109_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1590\/S1980-5764-2016DN1002003","volume":"10","author":"LP Schilling","year":"2016","unstructured":"Schilling LP, Zimmer ER, Shin M, Leuzy A, Pascoal TA, Benedet AL, et al. Imaging Alzheimer\u2019s disease pathophysiology with PET. Dement Neuropsychol. 2016;10(2):79\u201390. https:\/\/doi.org\/10.1590\/S1980-5764-2016DN1002003.","journal-title":"Dement Neuropsychol"},{"issue":"10","key":"6109_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2012;366(10):893\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa1106668.","journal-title":"N Engl J Med"},{"issue":"18","key":"6109_CR8","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/hbm.24782","volume":"40","author":"A Chandra","year":"2019","unstructured":"Chandra A, Valkimadi P-E, Pagano G, Cousins O, Dervenoulas G, Politis M. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer\u2019s disease and mild cognitive impairment. Hum Brain Mapp. 2019;40(18):5424\u201342. https:\/\/doi.org\/10.1002\/hbm.24782.","journal-title":"Hum Brain Mapp"},{"key":"6109_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"7618","key":"6109_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"issue":"12","key":"6109_CR11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Aducanumab: first approval. Drugs. 2021;81(12):1437\u201343. https:\/\/doi.org\/10.1007\/s40265-021-01569-z.","journal-title":"Drugs"},{"issue":"7","key":"6109_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","volume":"15","author":"DJ Selkoe","year":"2019","unstructured":"Selkoe DJ. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol. 2019;15(7):365\u20136. https:\/\/doi.org\/10.1038\/s41582-019-0205-1.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"6109_CR13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.tins.2015.08.003","volume":"38","author":"BW Chow","year":"2015","unstructured":"Chow BW, Gu C. The molecular constituents of the blood-brain barrier. Trends Neurosci. 2015;38(10):598\u2013608. https:\/\/doi.org\/10.1016\/j.tins.2015.08.003.","journal-title":"Trends Neurosci"},{"issue":"10","key":"6109_CR14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41593-018-0234-x","volume":"21","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018;21(10):1318\u201331. https:\/\/doi.org\/10.1038\/s41593-018-0234-x.","journal-title":"Nat Neurosci"},{"issue":"9","key":"6109_CR15","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","volume":"24","author":"AR Jones","year":"2007","unstructured":"Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24(9):1759\u201371. https:\/\/doi.org\/10.1007\/s11095-007-9379-0.","journal-title":"Pharm Res"},{"issue":"3","key":"6109_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","volume":"10","author":"YJ Yu","year":"2013","unstructured":"Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013;10(3):459\u201372. https:\/\/doi.org\/10.1007\/s13311-013-0187-4.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"6109_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021;20(5):362\u201383. https:\/\/doi.org\/10.1038\/s41573-021-00139-y.","journal-title":"Nat Rev Drug Discov"},{"key":"6109_CR18","doi-asserted-by":"publisher","unstructured":"Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545).\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aay1359.","DOI":"10.1126\/scitranslmed.aay1359"},{"issue":"1","key":"6109_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","volume":"22","author":"F Weber","year":"2018","unstructured":"Weber F, Bohrmann B, Niewoehner J, Fischer JAA, Rueger P, Tiefenthaler G, et al. Brain shuttle antibody for Alzheimer\u2019s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Rep. 2018;22(1):149\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2017.12.019.","journal-title":"Cell Rep"},{"issue":"5990","key":"6109_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/312162a0","volume":"312","author":"WA Jefferies","year":"1984","unstructured":"Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312(5990):162\u20133. https:\/\/doi.org\/10.1038\/312162a0.","journal-title":"Nature"},{"issue":"1","key":"6109_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/a:1006948027674","volume":"20","author":"T Moos","year":"2000","unstructured":"Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol. 2000;20(1):77\u201395. https:\/\/doi.org\/10.1023\/a:1006948027674.","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"6109_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm1315","volume":"5","author":"FR Maxfield","year":"2004","unstructured":"Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol. 2004;5(2):121\u201332. https:\/\/doi.org\/10.1038\/nrm1315.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6109_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","volume":"187","author":"CM Dawidczyk","year":"2014","unstructured":"Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release. 2014;187:133\u201344. https:\/\/doi.org\/10.1016\/j.jconrel.2014.05.036.","journal-title":"J Control Release."},{"issue":"11","key":"6109_CR24","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1073\/pnas.88.11.4771","volume":"88","author":"PM Friden","year":"1991","unstructured":"Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci U S A. 1991;88(11):4771\u20135. https:\/\/doi.org\/10.1073\/pnas.88.11.4771.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6109_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/bit.22135","volume":"102","author":"RJ Boado","year":"2009","unstructured":"Boado RJ, Zhang Y, Wang Y, Pardridge WM. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng. 2009;102(4):1251\u20138. https:\/\/doi.org\/10.1002\/bit.22135.","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"6109_CR26","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep. 2018;8(1):6412. https:\/\/doi.org\/10.1038\/s41598-018-24501-0.","journal-title":"Sci Rep"},{"issue":"4","key":"6109_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.119.239558","volume":"62","author":"GAMS van Dongen","year":"2021","unstructured":"van Dongen GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, et al. The role of 89Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals. J Nucl Med. 2021;62(4):438\u201345. https:\/\/doi.org\/10.2967\/jnumed.119.239558.","journal-title":"J Nucl Med"},{"key":"6109_CR28","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1038\/ncomms10759","volume":"7","author":"D Sehlin","year":"2016","unstructured":"Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syv\u00e4nen S. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease. Nat Commun. 2016;7:10759. https:\/\/doi.org\/10.1038\/ncomms10759.","journal-title":"Nat Commun."},{"issue":"2","key":"6109_CR29","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist G, Syv\u00e4nen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7(2):308\u201318. https:\/\/doi.org\/10.7150\/thno.17155.","journal-title":"Theranostics"},{"key":"6109_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","volume":"184","author":"XT Fang","year":"2019","unstructured":"Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syv\u00e4nen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;184:881\u20138. https:\/\/doi.org\/10.1016\/j.neuroimage.2018.10.011.","journal-title":"Neuroimage."},{"issue":"1","key":"6109_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13550-021-00799-2","volume":"11","author":"M Chomet","year":"2021","unstructured":"Chomet M, Schreurs M, Vos R, Verlaan M, Kooijman EJ, Poot AJ, et al. Performance of nanoScan PET\/CT and PET\/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice. EJNMMI Res. 2021;11(1):57. https:\/\/doi.org\/10.1186\/s13550-021-00799-2.","journal-title":"EJNMMI Res"},{"issue":"3","key":"6109_CR32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00259-020-05002-7","volume":"48","author":"M Chomet","year":"2021","unstructured":"Chomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, et al. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging. 2021;48(3):694\u2013707. https:\/\/doi.org\/10.1007\/s00259-020-05002-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"6109_CR33","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.7150\/thno.73509","volume":"12","author":"TE Wuensche","year":"2022","unstructured":"Wuensche TE, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman EJM, et al. Advancing